# US 2025/0213632 A1 · Composition for ameliorating side effects caused by cancer treatment comprising lactobacillus fermentum hem1036 strain as active ingredient

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0213632 A1
- Document ID: US20250213632A1
- Status: Published application
- Kind: A1
- Application number: 19/087,756
- Filed: 2025-03-24
- Published: 2025-07-03
- Earliest claimed: 2022-09-30
- Assignees: Hem Pharma Inc.
- Applicants: Hem Pharma Inc.
- Inventors: Yo Sep JI; So Young PARK; Hye Ji KANG; Bo Bae KIM
- Web page: https://patentgrep.com/patent/US20250213632A1

## CPC

- A61K 35/747: Lactobacilli, e.g. L. acidophilus or L. brevis
- A23L 33/135: Bacteria or derivatives thereof, e.g. probiotics
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/12: Antidiarrhoeals
- A61P 3/02: Nutrients, e.g. vitamins, minerals
- C12N 1/20: Bacteria; Culture media therefor
- C12N 1/205: Bacterial isolates
- A61K 2035/115: {Probiotics}
- C12R 2001/225: Lactobacillus
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12R: INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS

## Abstract

A composition for ameliorating side effects of cancer treatment, comprising a strain Lactobacillus fermentum HEM1036 (KCTC13978BP) as an active ingredient according to an embodiment of the present disclosure can prevent or treat side effects caused by cancer treatment or intake of anti-cancer agents through regulation of short-chain fatty acids and modulation of gut microbiota, and the composition can be applied to food compositions, health functional food compositions, pharmaceutical compositions, etc. Under the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure, the Lactobacillus fermentum HEM1036 strain was deposited with the international depositary authority: the Korean Collection for Type Cultures on Oct. 8, 2019, under the Accession Number: KCTC 13978BP.

## Claims

### Claim 1

A composition for ameliorating side effects of cancer treatment, comprising a strain Lactobacillus fermentum HEM1036 deposited with the Korean Collection for Type Cultures under Accession No. KCTC13978BP as an active ingredient,
wherein the side effects of cancer treatment include low anterior resection syndrome (LARS), diarrhea, or weight loss.

### Claim 2 (depends on 1)

The composition of claim 1,
wherein the composition decreases the levels of total short-chain fatty acids (total SCFA) and acetate.

### Claim 3 (depends on 1)

The composition of claim 1,
wherein the composition decreases the expression level of TNFα or IL-1β.

### Claim 4 (depends on 1)

The composition of claim 1,
wherein the composition increases the expression of one or more selected from the protein group consisting of Clca1, CFTR, ANO1, NKCC1, NHE3, SGLT1, and DRA.

### Claim 5 (depends on 1)

The composition of claim 1,
wherein the composition comprises a strain Lactobacillus fermentum HEM1036, live cells, heat-killed cells, culture fluid, fragments, or extracts thereof.

### Claim 6

A pharmaceutical composition for ameliorating side effects of cancer treatment, comprising a strain Lactobacillus fermentum HEM1036 deposited with the Korean Collection for Type Cultures under Accession No. KCTC13978BP as an active ingredient,
wherein the side effects of cancer treatment include LARS, diarrhea, or weight loss.

### Claim 7 (depends on 1)

A method for ameliorating side effects of cancer treatment, comprising:
administering the composition of claim 1.
